Improving treatments for prostate cancer by targeting androgen signaling
Enhancing the efficacy of androgen signaling inhibitors in prostate cancer
This study is looking at ways to make treatments for castration-resistant prostate cancer work better by understanding why some patients don't respond to current therapies, with the hope of finding new options that could help improve their health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-10877749 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of androgen signaling inhibitors, which are crucial in treating castration-resistant prostate cancer (CRPC). The team is investigating the mechanisms behind resistance to these inhibitors, using advanced bioinformatics to analyze data from prostate cancer cells and tumors. By identifying new pathways that contribute to this resistance, the research aims to develop novel therapeutic strategies that could improve patient outcomes. Patients may benefit from new treatment options that are more effective than current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with castration-resistant prostate cancer who have not responded adequately to current androgen signaling inhibitors.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone treatment with androgen signaling inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for prostate cancer, potentially extending survival and improving quality of life for patients.
How similar studies have performed: Previous research has shown promise in targeting androgen signaling pathways, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Liu, Xiaoqi — University of Kentucky
- Study coordinator: Liu, Xiaoqi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.